Contact PI/Project LeaderHUMPHREYS-BEHER, MICHAEL G
Awardee OrganizationUNIVERSITY OF FLORIDA
Description
Abstract Text
Chronic injections of the beta-adrenergic agonist, isoproterenol, produce
in addition to cell hypertrophy and hyperplasia, biochemical alterations in
protein synthesis in the rat and mouse parotid gland. Among the
biochemical changes is an increase in specific activity and topography for
an enzyme normally thought of as a Golgi membrane marker enzyme 4beta-
galactosyltransferase (Gal Tase). A similar change in enzyme activity and
localization is observed with the introduction of dietary and hormonal
changes that result in an increased functional gland activity and resulting
hyperplasia. The importance of the up-regulation and surface localization
of Gal Tase became apparent in experiments in which agents that interact
with this enzyme were shown to severely inhibit parotid gland hypertrophy
and hyperplasia in vivo or in vitro. A cDNA clone has been isolated which
specifically modulates the cell surface appearance of Gal Tase and
therefore acinar cell growth. Sequence analysis of a partial cDNA
indicated homology to a class of enzymes involved in cell division. The
clone designated GTA (Gal Tase activator) is a Ca+2/calmodulin dependent
serine protein kinase which is induced in parotid cells in response to
isoproterenol. The substrate of the kinase Golgi localized Gal Tase, which
upon phosphorylation, is targeted to the plasma membrane. Numerous reports
have shown that alteration of cell surface Gal Tase activity might be
involved in cell adhesion, differentiation and tumorogenesis. We therefore
believe that studies of the regulation of the GTA gene are crucial to
understanding growth control of parotid and other tissues regulated by
surface Gal Tase. To accomplish this, the GTA cDNA will be used to isolate
chromosomal sequences which will be analyzed for organization of regulatory
sequences as well as intron and exon structure. The GTA cDNA will allow us
to examine at the molecular level, the effects that gene expression and
cell surface localization of Gal Tase have on acinar cell growth in vivo
and in vitro. The GTA protein will be isolated and biochemically analyzed;
using the purified protein for antibody production and immunohistological
studies. Finally, we will continue to investigate the sequence of
intracellular events involved in the signal transduction from beta-agonist
to the nucleus causing expression of GTA, and the action of Gal Tase in the
plasma membrane in perpetuating the signal for acinar cell proliferation.
These findings will ultimately be used to evaluate the contribution of GTA
expression and galactosyltransferase-mediated cell proliferation in human
pathologies of the oral cavity, and in particular, disorders of the
salivary glands involving tissue hypertrophy and hyperplasia.
National Institute of Dental and Craniofacial Research
CFDA Code
DUNS Number
969663814
UEI
NNFQH1JAPEP3
Project Start Date
01-May-1988
Project End Date
30-April-1996
Budget Start Date
01-May-1994
Budget End Date
30-April-1995
Project Funding Information for 1994
Total Funding
$185,491
Direct Costs
$127,925
Indirect Costs
$57,566
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Dental and Craniofacial Research
$185,491
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DE008778-07
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DE008778-07
Patents
No Patents information available for 5R01DE008778-07
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DE008778-07
Clinical Studies
No Clinical Studies information available for 5R01DE008778-07
News and More
Related News Releases
No news release information available for 5R01DE008778-07
History
No Historical information available for 5R01DE008778-07
Similar Projects
No Similar Projects information available for 5R01DE008778-07